

James E Bradner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3697203/publications.pdf>

Version: 2024-02-01

211
papers

40,251
citations

4103

90
h-index

3254

191
g-index

219
all docs

219
docs citations

219
times ranked

47363
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of EZH2 transactivation function sensitizes solid tumors to genotoxic stress. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	3.3	22
2	A novel β -catenin/BCL9 complex inhibitor blocks oncogenic Wnt signaling and disrupts cholesterol homeostasis in colorectal cancer. Science Advances, 2022, 8, eabm3108.	4.7	10
3	An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity. Cell Chemical Biology, 2021, 28, 802-812.e6.	2.5	25
4	Multiple screening approaches reveal HDAC6 as a novel regulator of glycolytic metabolism in triple-negative breast cancer. Science Advances, 2021, 7, .	4.7	38
5	Functional Genomics Identify Distinct and Overlapping Genes Mediating Resistance to Different Classes of Heterobifunctional Degraders of Oncoproteins. Cell Reports, 2021, 34, 108532.	2.9	54
6	Targeting oncoproteins with a positive selection assay for protein degraders. Science Advances, 2021, 7, .	4.7	26
7	The synergy of BET inhibitors with aurora A kinase inhibitors in MYCN-amplified neuroblastoma is heightened with functional TP53. Neoplasia, 2021, 23, 624-633.	2.3	8
8	Selective targeting of MYC mRNA by stabilized antisense oligonucleotides. Oncogene, 2021, 40, 6527-6539.	2.6	5
9	Inhibition of Polo-like kinase 1 (PLK1) facilitates the elimination of HIV-1 viral reservoirs in CD4 ⁺ T cells ex vivo. Science Advances, 2020, 6, eaba1941.	4.7	16
10	Rapid and direct control of target protein levels with VHL-recruiting dTAG molecules. Nature Communications, 2020, 11, 4687.	5.8	129
11	Evolutionary conserved NSL complex/BRD4 axis controls transcription activation via histone acetylation. Nature Communications, 2020, 11, 2243.	5.8	21
12	Selective Mediator dependence of cell-type-specifying transcription. Nature Genetics, 2020, 52, 719-727.	9.4	84
13	Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer. Molecular Cell, 2020, 78, 1096-1113.e8.	4.5	114
14	BET bromodomain proteins regulate transcriptional reprogramming in genetic dilated cardiomyopathy. JCI Insight, 2020, 5, .	2.3	23
15	Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma. Journal of Clinical Investigation, 2020, 130, 5875-5892.	3.9	40
16	PAX8 activates metabolic genes via enhancer elements in Renal Cell Carcinoma. Nature Communications, 2019, 10, 3739.	5.8	49
17	Maintenance and enhancement of human peripheral blood mobilized stem/progenitor cell engraftment after ex vivo culture via an HDACi/SALL4 axis (3465). Experimental Hematology, 2019, 75, 53-63.e11.	0.2	5
18	Dual Inhibition of TAF1 and BET Bromodomains from the BI-2536 Kinase Inhibitor Scaffold. ACS Medicinal Chemistry Letters, 2019, 10, 1443-1449.	1.3	11

#	ARTICLE	IF	CITATIONS
19	High-fat diet fuels prostate cancer progression by rewiring the metabolome and amplifying the MYC program. <i>Nature Communications</i> , 2019, 10, 4358.	5.8	109
20	Small-molecule targeting of brachyury transcription factor addiction in chordoma. <i>Nature Medicine</i> , 2019, 25, 292-300.	15.2	120
21	The BET inhibitor JQ1 attenuates double-strand break repair and sensitizes models of pancreatic ductal adenocarcinoma to PARP inhibitors. <i>EBioMedicine</i> , 2019, 44, 419-430.	2.7	76
22	MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation. <i>Nature Genetics</i> , 2019, 51, 990-998.	9.4	61
23	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. <i>Nature Communications</i> , 2019, 10, 2400.	5.8	37
24	Enhancer Domains in Gastrointestinal Stromal Tumor Regulate KIT Expression and Are Targetable by BET Bromodomain Inhibition. <i>Cancer Research</i> , 2019, 79, 994-1009.	0.4	17
25	Small-molecule BCL6 inhibitor effectively treats mice with nonsclerodermatous chronic graft-versus-host disease. <i>Blood</i> , 2019, 133, 94-99.	0.6	21
26	Combined BET bromodomain and CDK2 inhibition in MYC-driven medulloblastoma. <i>Oncogene</i> , 2018, 37, 2850-2862.	2.6	71
27	Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands. <i>Nature Chemical Biology</i> , 2018, 14, 405-412.	3.9	176
28	BET bromodomain proteins regulate enhancer function during adipogenesis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, 2144-2149.	3.3	65
29	Enhancer invasion shapes MYCN-dependent transcriptional amplification in neuroblastoma. <i>Nature Genetics</i> , 2018, 50, 515-523.	9.4	163
30	Targeting the CoREST complex with dual histone deacetylase and demethylase inhibitors. <i>Nature Communications</i> , 2018, 9, 53.	5.8	175
31	Translation Termination Factor GSPT1 Is a Phenotypically Relevant Off-Target of Heterobifunctional Phthalimide Degraders. <i>ACS Chemical Biology</i> , 2018, 13, 553-560.	1.6	128
32	Pharmacological perturbation of CDK9 using selective CDK9 inhibition or degradation. <i>Nature Chemical Biology</i> , 2018, 14, 163-170.	3.9	376
33	The dTAG system for immediate and target-specific protein degradation. <i>Nature Chemical Biology</i> , 2018, 14, 431-441.	3.9	629
34	Diminished microRNA-29b level is associated with BRD4-mediated activation of oncogenes in cutaneous T-cell lymphoma. <i>Blood</i> , 2018, 131, 771-781.	0.6	42
35	R-2HG Exhibits Anti-tumor Activity by Targeting FTO/m6A/MYC/CEBPA Signaling. <i>Cell</i> , 2018, 172, 90-105.e23.	13.5	794
36	Dual Targeting of Oncogenic Activation and Inflammatory Signaling Increases Therapeutic Efficacy in Myeloproliferative Neoplasms. <i>Cancer Cell</i> , 2018, 33, 29-43.e7.	7.7	186

#	ARTICLE	IF	CITATIONS
37	A Chemoproteomic Approach to Query the Degradable Kinome Using a Multi-kinase Degradator. <i>Cell Chemical Biology</i> , 2018, 25, 88-99.e6.	2.5	313
38	JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 107-118.	1.9	27
39	Leukemia-specific delivery of mutant NOTCH1 targeted therapy. <i>Journal of Experimental Medicine</i> , 2018, 215, 197-216.	4.2	30
40	Enhancer Architecture and Essential Core Regulatory Circuitry of Chronic Lymphocytic Leukemia. <i>Cancer Cell</i> , 2018, 34, 982-995.e7.	7.7	101
41	Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma. <i>Cell Reports</i> , 2018, 25, 3693-3705.e6.	2.9	23
42	A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation. <i>Nature Cell Biology</i> , 2018, 20, 1410-1420.	4.6	265
43	NK Cells Mediate Synergistic Antitumor Effects of Combined Inhibition of HDAC6 and BET in a SCLC Preclinical Model. <i>Cancer Research</i> , 2018, 78, 3709-3717.	0.4	38
44	Targetable BET proteins- and E2F1-dependent transcriptional program maintains the malignancy of glioblastoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5086-E5095.	3.3	87
45	Structural and Atropisomeric Factors Governing the Selectivity of Pyrimido-benzodiazepinones as Inhibitors of Kinases and Bromodomains. <i>ACS Chemical Biology</i> , 2018, 13, 2438-2448.	1.6	44
46	Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7785-7795.	2.9	46
47	Gastrointestinal stromal tumor enhancers support a transcription factor network predictive of clinical outcome. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E5746-E5755.	3.3	20
48	Plasticity in binding confers selectivity in ligand-induced protein degradation. <i>Nature Chemical Biology</i> , 2018, 14, 706-714.	3.9	391
49	Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma. <i>ELife</i> , 2018, 7, .	2.8	125
50	A chemical probe toolbox for dissecting the cancer epigenome. <i>Nature Reviews Cancer</i> , 2017, 17, 160-183.	12.8	76
51	ENL links histone acetylation to oncogenic gene expression in acute myeloid leukaemia. <i>Nature</i> , 2017, 543, 265-269.	13.7	203
52	Transcription control by the ENL YEATS domain in acute leukaemia. <i>Nature</i> , 2017, 543, 270-274.	13.7	248
53	Synthesis and Biochemical Evaluation of Biotinylated Conjugates of Largazole Analogues: Selective Class I Histone Deacetylase Inhibitors. <i>Israel Journal of Chemistry</i> , 2017, 57, 319-330.	1.0	3
54	Transcriptional Addiction in Cancer. <i>Cell</i> , 2017, 168, 629-643.	13.5	843

#	ARTICLE	IF	CITATIONS
55	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. <i>Cell Reports</i> , 2017, 18, 2162-2174.	2.9	244
56	Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined Histone Deacetylase and Bromodomain Inhibition in Non-Small Cell Lung Cancer. <i>Cancer Discovery</i> , 2017, 7, 852-867.	7.7	132
57	Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands. <i>Angewandte Chemie - International Edition</i> , 2017, 56, 5738-5743.	7.2	207
58	Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands. <i>Angewandte Chemie</i> , 2017, 129, 5832-5837.	1.6	14
59	Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	53
60	BET bromodomain inhibition suppresses innate inflammatory and profibrotic transcriptional networks in heart failure. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	203
61	BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 4805-4817.	2.9	39
62	Gene expression profiling of patient-derived pancreatic cancer xenografts predicts sensitivity to the BET bromodomain inhibitor JQ1: implications for individualized medicine efforts. <i>EMBO Molecular Medicine</i> , 2017, 9, 482-497.	3.3	66
63	Pojamide: An HDAC3-Selective Ferrocene Analogue with Remarkably Enhanced Redox-Triggered Ferrocenium Activity in Cells. <i>Organometallics</i> , 2017, 36, 3276-3283.	1.1	28
64	HIF activation causes synthetic lethality between the VHL tumor suppressor and the EZH1 histone methyltransferase. <i>Science Translational Medicine</i> , 2017, 9, .	5.8	36
65	Hotspots of aberrant enhancer activity punctuate the colorectal cancer epigenome. <i>Nature Communications</i> , 2017, 8, 14400.	5.8	93
66	Epigenetic Reprogramming of Lineage-Committed Human Mammary Epithelial Cells Requires DNMT3A and Loss of DOT1L. <i>Stem Cell Reports</i> , 2017, 9, 943-955.	2.3	16
67	Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. <i>Nature Medicine</i> , 2017, 23, 1063-1071.	15.2	240
68	YY1 Is a Structural Regulator of Enhancer-Promoter Loops. <i>Cell</i> , 2017, 171, 1573-1588.e28.	13.5	749
69	Synthetic transcription elongation factors license transcription across repressive chromatin. <i>Science</i> , 2017, 358, 1617-1622.	6.0	110
70	BET Bromodomain Proteins Function as Master Transcription Elongation Factors Independent of CDK9 Recruitment. <i>Molecular Cell</i> , 2017, 67, 5-18.e19.	4.5	347
71	Inhibition of BET proteins and epigenetic signaling as a potential treatment for osteoporosis. <i>Bone</i> , 2017, 94, 10-21.	1.4	51
72	A Novel Bromodomain Inhibitor Reverses HIV-1 Latency through Specific Binding with BRD4 to Promote Tat and P-TEFb Association. <i>Frontiers in Microbiology</i> , 2017, 8, 1035.	1.5	45

#	ARTICLE	IF	CITATIONS
73	MELK is not necessary for the proliferation of basal-like breast cancer cells. <i>ELife</i> , 2017, 6, .	2.8	86
74	CRISPR-Cas9 screen reveals a MYCN-amplified neuroblastoma dependency on EZH2. <i>Journal of Clinical Investigation</i> , 2017, 128, 446-462.	3.9	117
75	Merkel cell polyomavirus recruits MYCL to the EP400 complex to promote oncogenesis. <i>PLoS Pathogens</i> , 2017, 13, e1006668.	2.1	84
76	Targeting the epigenetic readers in Ewing Sarcoma inhibits the oncogenic transcription factor EWS/Fli1. <i>Oncotarget</i> , 2016, 7, 24125-24140.	0.8	42
77	Ligand-Promoted <i>meta</i> -C ¹⁴ H Arylation of Anilines, Phenols, and Heterocycles. <i>Journal of the American Chemical Society</i> , 2016, 138, 9269-9276.	6.6	216
78	An oncogenic Ezh2 mutation induces tumors through global redistribution of histone 3 lysine 27 trimethylation. <i>Nature Medicine</i> , 2016, 22, 632-640.	15.2	176
79	High-Resolution Mapping of RNA Polymerases Identifies Mechanisms of Sensitivity and Resistance to BET Inhibitors in t(8;21) AML. <i>Cell Reports</i> , 2016, 16, 2003-2016.	2.9	69
80	Signal-Dependent Recruitment of BRD4 to Cardiomyocyte Super-Enhancers Is Suppressed by a MicroRNA. <i>Cell Reports</i> , 2016, 16, 1366-1378.	2.9	70
81	Bromodomain and Extraterminal Protein Inhibition Blocks Growth of Triple-negative Breast Cancers through the Suppression of Aurora Kinases. <i>Journal of Biological Chemistry</i> , 2016, 291, 23756-23768.	1.6	48
82	Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck. <i>Cancer</i> , 2016, 122, 3632-3640.	2.0	145
83	BET and BRAF inhibitors act synergistically against BRAF ^{v600E} mutant melanoma. <i>Cancer Medicine</i> , 2016, 5, 1183-1193.	1.3	41
84	Development of a Potent and Selective HDAC8 Inhibitor. <i>ACS Medicinal Chemistry Letters</i> , 2016, 7, 929-932.	1.3	59
85	Targeting Chromatin Regulators Inhibits Leukemogenic Gene Expression in <i>NPM1</i> Mutant Leukemia. <i>Cancer Discovery</i> , 2016, 6, 1166-1181.	7.7	171
86	BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. <i>Cell Reports</i> , 2016, 16, 2829-2837.	2.9	331
87	Chronic Myelogenous Leukemia ¹ Initiating Cells Require Polycomb Group Protein EZH2. <i>Cancer Discovery</i> , 2016, 6, 1237-1247.	7.7	72
88	Mechanism, Consequences, and Therapeutic Targeting of Abnormal IL15 Signaling in Cutaneous T-cell Lymphoma. <i>Cancer Discovery</i> , 2016, 6, 986-1005.	7.7	79
89	BET Inhibition Induces Apoptosis in Aggressive B-Cell Lymphoma via Epigenetic Regulation of BCL-2 Family Members. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 2030-2041.	1.9	57
90	Assessment of Bromodomain Target Engagement by a Series of BI2536 Analogues with Miniaturized BET-BRET. <i>ChemMedChem</i> , 2016, 11, 2575-2581.	1.6	17

#	ARTICLE	IF	CITATIONS
91	Relative Binding Free Energy Calculations Applied to Protein Homology Models. <i>Journal of Chemical Information and Modeling</i> , 2016, 56, 2388-2400.	2.5	60
92	Design and characterization of bivalent BET inhibitors. <i>Nature Chemical Biology</i> , 2016, 12, 1089-1096.	3.9	115
93	BET Inhibitors Suppress ALDH Activity by Targeting <i>ALDH1A1</i> Super-Enhancer in Ovarian Cancer. <i>Cancer Research</i> , 2016, 76, 6320-6330.	0.4	115
94	Discovery of selective small-molecule HDAC6 inhibitor for overcoming proteasome inhibitor resistance in multiple myeloma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 13162-13167.	3.3	112
95	Eradication of Acute Myeloid Leukemia with FLT3 Ligand-Targeted miR-150 Nanoparticles. <i>Cancer Research</i> , 2016, 76, 4470-4480.	0.4	48
96	PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. <i>Cell Reports</i> , 2016, 15, 2692-2704.	2.9	92
97	Oncogenic Deregulation of EZH2 as an Opportunity for Targeted Therapy in Lung Cancer. <i>Cancer Discovery</i> , 2016, 6, 1006-1021.	7.7	108
98	Active medulloblastoma enhancers reveal subgroup-specific cellular origins. <i>Nature</i> , 2016, 530, 57-62.	13.7	318
99	Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. <i>Cell</i> , 2016, 164, 293-309.	13.5	399
100	<i>MTAP</i> deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells. <i>Science</i> , 2016, 351, 1214-1218.	6.0	396
101	Models of human core transcriptional regulatory circuitries. <i>Genome Research</i> , 2016, 26, 385-396.	2.4	223
102	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. <i>Nature Genetics</i> , 2016, 48, 273-282.	9.4	214
103	Response and resistance to BET bromodomain inhibitors in triple-negative breast cancer. <i>Nature</i> , 2016, 529, 413-417.	13.7	490
104	The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects. <i>Clinical Cancer Research</i> , 2016, 22, 2534-2544.	3.2	100
105	Multi-focal control of mitochondrial gene expression by oncogenic MYC provides potential therapeutic targets in cancer. <i>Oncotarget</i> , 2016, 7, 72395-72414.	0.8	30
106	A Bead-Based Proximity Assay for BRD4 Ligand Discovery. <i>Current Protocols in Chemical Biology</i> , 2015, 7, 263-278.	1.7	21
107	Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. <i>Blood</i> , 2015, 126, 1565-1574.	0.6	92
108	The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation. <i>Journal of Cellular Physiology</i> , 2015, 230, 2683-2694.	2.0	58

#	ARTICLE	IF	CITATIONS
109	Phthalimide conjugation as a strategy for in vivo target protein degradation. <i>Science</i> , 2015, 348, 1376-1381.	6.0	1,244
110	Tag and Capture Flow Hydrogen Exchange Mass Spectrometry with a Fluorous-Immobilized Probe. <i>Analytical Chemistry</i> , 2015, 87, 6349-6356.	3.2	1
111	An in-tumor genetic screen reveals that the BET bromodomain protein, BRD4, is a potential therapeutic target in ovarian carcinoma. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 232-237.	3.3	136
112	Structure-Guided DOT1L Probe Optimization by Label-Free Ligand Displacement. <i>ACS Chemical Biology</i> , 2015, 10, 667-674.	1.6	20
113	MLL partial tandem duplication leukemia cells are sensitive to small molecule DOT1L inhibition. <i>Haematologica</i> , 2015, 100, e190-e193.	1.7	45
114	Therapeutic targeting of BET bromodomain protein, Brd4, delays cyst growth in ADPKD. <i>Human Molecular Genetics</i> , 2015, 24, 3982-3993.	1.4	51
115	An essential passenger with p53. <i>Nature</i> , 2015, 520, 626-627.	13.7	19
116	Convergence of Developmental and Oncogenic Signaling Pathways at Transcriptional Super-Enhancers. <i>Molecular Cell</i> , 2015, 58, 362-370.	4.5	382
117	Acetylation site specificities of lysine deacetylase inhibitors in human cells. <i>Nature Biotechnology</i> , 2015, 33, 415-423.	9.4	237
118	Selective inhibition of protein arginine methyltransferase 5 blocks initiation and maintenance of B-cell transformation. <i>Blood</i> , 2015, 125, 2530-2543.	0.6	125
119	RNA Exosome-Regulated Long Non-Coding RNA Transcription Controls Super-Enhancer Activity. <i>Cell</i> , 2015, 161, 774-789.	13.5	370
120	DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia. <i>Nature Medicine</i> , 2015, 21, 335-343.	15.2	200
121	Modular synthesis and biological activity of pyridyl-based analogs of the potent Class I Histone Deacetylase Inhibitor Largazole. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5061-5074.	1.4	32
122	Chromatin proteomic profiling reveals novel proteins associated with histone-marked genomic regions. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 3841-3846.	3.3	123
123	Combined inhibition of BET family proteins and histone deacetylases as a potential epigenetics-based therapy for pancreatic ductal adenocarcinoma. <i>Nature Medicine</i> , 2015, 21, 1163-1171.	15.2	349
124	Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset. <i>Cancer Discovery</i> , 2015, 5, 1210-1223.	7.7	575
125	Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. <i>Journal of Experimental Medicine</i> , 2015, 212, 1819-1832.	4.2	137
126	Targeting chromatin binding regulation of constitutively active AR variants to overcome prostate cancer resistance to endocrine-based therapies. <i>Nucleic Acids Research</i> , 2015, 43, 5880-5897.	6.5	136

#	ARTICLE	IF	CITATIONS
127	Deregulation of the Ras-Erk Signaling Axis Modulates the Enhancer Landscape. <i>Cell Reports</i> , 2015, 12, 1300-1313.	2.9	37
128	Transcriptional and post-transcriptional control of adipocyte differentiation by Jumonji domain-containing protein 6. <i>Nucleic Acids Research</i> , 2015, 43, 7790-7804.	6.5	33
129	Inhibitors of emerging epigenetic targets for cancer therapy: a patent review (2010–2014). <i>Pharmaceutical Patent Analyst</i> , 2015, 4, 261-284.	0.4	36
130	Inhibition of Bromodomain Proteins for the Treatment of Human Diffuse Large B-cell Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 113-122.	3.2	119
131	High Throughput Screening Identifies Potential Inhibitors of WHSC1/MMSET, a Histone Methyltransferase Oncoprotein in Multiple Myeloma and Acute Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 3251-3251.	0.6	1
132	Targeted Treatment of FLT3 -Overexpressing Acute Myeloid Leukemia with MiR-150 Nanoparticles Guided By Conjugated FLT3 Ligand Peptides. <i>Blood</i> , 2015, 126, 3784-3784.	0.6	2
133	Enhancer Landscapes Reveal Transcription Factor Network Dependencies in Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 436-436.	0.6	3
134	JQ1, a Selective Bromodomain Inhibitor, Augment the Immunogenicity of Mantle Cell Lymphoma By Influencing the Expression of PD-L1. <i>Blood</i> , 2015, 126, 822-822.	0.6	3
135	Structural Dynamics of the NSD Family Histone Methyltransferases. <i>FASEB Journal</i> , 2015, 29, 717.13.	0.2	0
136	Abstract A41: Shaping Myc-dependent transcriptional amplification. , 2015, , .		0
137	Dose-dependent role of the cohesin complex in normal and malignant hematopoiesis. <i>Journal of Cell Biology</i> , 2015, 211, 21110IA226.	2.3	0
138	Dose-Dependent Role of the Cohesin Complex in Normal and Malignant Hematopoiesis. <i>Blood</i> , 2015, 126, 435-435.	0.6	1
139	Genome-Wide Mapping Reveals BRD4 in Regulation of Tumor-Driver Genes in Cutaneous T-Cell Lymphoma. <i>Blood</i> , 2015, 126, 589-589.	0.6	2
140	Discovery and Characterization of Promoter and Super-Enhancer-Associated Dependencies through E2F and BET Bromodomains in Multiple Myeloma. <i>Blood</i> , 2015, 126, 838-838.	0.6	1
141	Therapeutic Strategies to Inhibit MYC. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2014, 4, a014266-a014266.	2.9	180
142	Convergent Transcription at Intragenic Super-Enhancers Targets AID-Initiated Genomic Instability. <i>Cell</i> , 2014, 159, 1538-1548.	13.5	221
143	Identification of ATR–Chk1 Pathway Inhibitors That Selectively Target p53-Deficient Cells without Directly Suppressing ATR Catalytic Activity. <i>Cancer Research</i> , 2014, 74, 7534-7545.	0.4	25
144	AF10 Regulates Progressive H3K79 Methylation and HOX Gene Expression in Diverse AML Subtypes. <i>Cancer Cell</i> , 2014, 26, 896-908.	7.7	153

#	ARTICLE	IF	CITATIONS
145	Targeting Transcriptional Addictions in Small Cell Lung Cancer with a Covalent CDK7 Inhibitor. <i>Cancer Cell</i> , 2014, 26, 909-922.	7.7	376
146	From transcriptional regulation to drugging the cancer epigenome. <i>Genome Medicine</i> , 2014, 6, 123.	3.6	1
147	Activation of <i>SOX2</i> Expression by BRD4-NUT Oncogenic Fusion Drives Neoplastic Transformation in NUT Midline Carcinoma. <i>Cancer Research</i> , 2014, 74, 3332-3343.	0.4	53
148	Quantitative CHIP-Seq Normalization Reveals Global Modulation of the Epigenome. <i>Cell Reports</i> , 2014, 9, 1163-1170.	2.9	442
149	The use of small molecules in somatic-cell reprogramming. <i>Trends in Cell Biology</i> , 2014, 24, 179-187.	3.6	60
150	An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia. <i>Nature Genetics</i> , 2014, 46, 364-370.	9.4	333
151	Triplication of a 21q22 region contributes to B cell transformation through HMG1 overexpression and loss of histone H3 Lys27 trimethylation. <i>Nature Genetics</i> , 2014, 46, 618-623.	9.4	117
152	MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia. <i>Cancer Cell</i> , 2014, 25, 652-665.	7.7	274
153	Selective inhibition of BET bromodomain epigenetic signalling interferes with the bone-associated tumour vicious cycle. <i>Nature Communications</i> , 2014, 5, 3511.	5.8	121
154	Genome-wide localization of small molecules. <i>Nature Biotechnology</i> , 2014, 32, 92-96.	9.4	165
155	BET Bromodomain Inhibition of <i>MYC</i> -Amplified Medulloblastoma. <i>Clinical Cancer Research</i> , 2014, 20, 912-925.	3.2	296
156	The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins. <i>Science</i> , 2014, 343, 305-309.	6.0	1,196
157	Biased Multicomponent Reactions to Develop Novel Bromodomain Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 9019-9027.	2.9	80
158	NF- κ B Directs Dynamic Super Enhancer Formation in Inflammation and Atherogenesis. <i>Molecular Cell</i> , 2014, 56, 219-231.	4.5	507
159	PRC2 loss amplifies Ras-driven transcription and confers sensitivity to BRD4-based therapies. <i>Nature</i> , 2014, 514, 247-251.	13.7	386
160	7,9-Diaryl-1,6,8-trioxaspiro[4.5]dec-3-en-2-ones: Readily accessible and highly potent anticancer compounds. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 4035-4038.	1.0	3
161	BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 2315-2327.	1.9	123
162	Targeting the MYC and PI3K Pathways Eliminates Leukemia-Initiating Cells in T-cell Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2014, 74, 7048-7059.	0.4	46

#	ARTICLE	IF	CITATIONS
163	Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. <i>Nature Medicine</i> , 2014, 20, 732-740.	15.2	255
164	A Single Oncogenic Enhancer Rearrangement Causes Concomitant EVI1 and GATA2 Deregulation in Leukemia. <i>Cell</i> , 2014, 157, 369-381.	13.5	571
165	An epigenomic approach to therapy for tamoxifen-resistant breast cancer. <i>Cell Research</i> , 2014, 24, 809-819.	5.7	155
166	Notch inhibition allows oncogene-independent generation of iPS cells. <i>Nature Chemical Biology</i> , 2014, 10, 632-639.	3.9	64
167	MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma. <i>Oncogene</i> , 2014, 33, 1736-1742.	2.6	155
168	SALL4 Is a Key Factor in HDAC Inhibitor Mediated Ex Vivo Expansion of Human Peripheral Blood Mobilized Stem/Progenitor CD34+CD90+ Cells. <i>Blood</i> , 2014, 124, 1566-1566.	0.6	3
169	Ongoing Spontaneous DNA Damage and the Role of Aberrant Epigenome in Multiple Myeloma. <i>Blood</i> , 2014, 124, 3398-3398.	0.6	2
170	Regulation of MYC Expression and Differential JQ1 Sensitivity in Cancer Cells. <i>PLoS ONE</i> , 2014, 9, e87003.	1.1	51
171	Disruption of the Ikaros-Mediated Gene Expression Program in Multiple Myeloma with Immunomodulatory Agents. <i>Blood</i> , 2014, 124, 420-420.	0.6	0
172	Structure-Guided Design of DOT1L Methyltransferase Inhibitors By a Novel, Label Free Assay Platform. <i>Blood</i> , 2014, 124, 4811-4811.	0.6	0
173	Superior Pre-Clinical Activity of BET (Bromodomain and Extra terminal) Protein Antagonist Combined with Ibrutinib, Panobinostat or Carfilzomib Against Human Mantle Cell Lymphoma (MCL) Cells. <i>Blood</i> , 2014, 124, 918-918.	0.6	1
174	Mechanistic Role of HEXIM1 Induction in BRD4-Antagonist Mediated Growth Inhibition, Differentiation and in Vivo Lethal Activity Against Human AML Blast Progenitor Cells. <i>Blood</i> , 2014, 124, 3534-3534.	0.6	0
175	BET acetyl-lysine binding proteins control pathological cardiac hypertrophy. <i>Journal of Molecular and Cellular Cardiology</i> , 2013, 63, 175-179.	0.9	154
176	Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma. <i>Cancer Cell</i> , 2013, 24, 777-790.	7.7	635
177	BET Bromodomains Mediate Transcriptional Pause Release in Heart Failure. <i>Cell</i> , 2013, 154, 569-582.	13.5	346
178	Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers. <i>Cell</i> , 2013, 153, 320-334.	13.5	2,366
179	The bromodomain protein Brd4 insulates chromatin from DNA damage signalling. <i>Nature</i> , 2013, 498, 246-250.	13.7	278
180	PFI-1, a Highly Selective Protein Interaction Inhibitor, Targeting BET Bromodomains. <i>Cancer Research</i> , 2013, 73, 3336-3346.	0.4	218

#	ARTICLE	IF	CITATIONS
181	BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. <i>Cell Cycle</i> , 2013, 12, 452-462.	1.3	209
182	Targeting MYCN in Neuroblastoma by BET Bromodomain Inhibition. <i>Cancer Discovery</i> , 2013, 3, 308-323.	7.7	549
183	Combined Therapy With BRD4 Antagonist and JAK Inhibitor Is Synergistically Lethal Against Human Myeloproliferative Neoplasm (MPN) Cells. <i>Blood</i> , 2013, 122, 2842-2842.	0.6	1
184	Genome-Wide RNAi Screen Identifies The Mechanistic Role For DOT1L In MLL-Rearranged Leukemia. <i>Blood</i> , 2013, 122, 598-598.	0.6	4
185	BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. <i>Blood</i> , 2012, 120, 2843-2852.	0.6	329
186	Small-Molecule Inhibition of BRDT for Male Contraception. <i>Cell</i> , 2012, 150, 673-684.	13.5	353
187	Transcriptional Amplification in Tumor Cells with Elevated c-Myc. <i>Cell</i> , 2012, 151, 56-67.	13.5	1,262
188	Chromatin modifications as therapeutic targets in MLL-rearranged leukemia. <i>Trends in Immunology</i> , 2012, 33, 563-570.	2.9	52
189	Phenothiazines Induce Apoptosis in T-Cell Acute Lymphoblastic Leukemia by Activating the Phosphatase Activity of the PP2A Tumor Suppressor. <i>Blood</i> , 2012, 120, 3558-3558.	0.6	2
190	Silencing c-Myc Using Myc Inhibitor JQ1 and EZH2 Inhibitor DZNep Blocks Converging Survival Signals in Aggressive B-Cell Lymphomas. <i>Blood</i> , 2012, 120, 4618-4618.	0.6	0
191	The Interaction Between DOT1L and AF10 Is Required for H3K79 Dimethylation and MLL-AF9 Leukemia. <i>Blood</i> , 2012, 120, 401-401.	0.6	0
192	Targeting Bromodomains in Myeloma. <i>Blood</i> , 2012, 120, SCI-6-SCI-6.	0.6	0
193	Targeting STAT5 in Leukemia Through Inhibition of Bromodomain Proteins. <i>Blood</i> , 2012, 120, 399-399.	0.6	1
194	Induction of Human Fetal Hemoglobin Expression by Selective Inhibitors of Histone Deacetylase 1 and 2 (HDAC1/2). <i>Blood</i> , 2012, 120, 3259-3259.	0.6	3
195	RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. <i>Nature</i> , 2011, 478, 524-528.	13.7	1,656
196	BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc. <i>Cell</i> , 2011, 146, 904-917.	13.5	2,432
197	Combined Autophagy and Proteasome Inhibition for Multiple Myeloma: Final Results of a Phase 1 Trial of Hydroxychloroquine and Standard Dose Bortezomib for Patients with Relapsed or Refractory Myeloma. <i>Blood</i> , 2011, 118, 1869-1869.	0.6	3
198	Inhibition of c-Myc Expression and Function in Hematologic Malignancies. <i>Blood</i> , 2011, 118, 1409-1409.	0.6	0

#	ARTICLE	IF	CITATIONS
199	Induction of Fetal Hemoglobin by Inactivation of HDAC1 or HDAC2 without Altering Cellular Proliferation. <i>Blood</i> , 2011, 118, 354-354.	0.6	0
200	Selective inhibition of BET bromodomains. <i>Nature</i> , 2010, 468, 1067-1073.	13.7	3,456
201	Chemical phylogenetics of histone deacetylases. <i>Nature Chemical Biology</i> , 2010, 6, 238-243.	3.9	646
202	Treatment with Histone Deacetylase 6-Specific Inhibitor WT-161 Disrupts hsp90 Function, Abrogates Aggresome Formation and Sensitizes Human Mantle Cell Lymphoma Cells to Lethal ER Stress Induced by Proteasome Inhibitor Carfilzomib. <i>Blood</i> , 2010, 116, 2856-2856.	0.6	5
203	Selective Inhibition of HDAC6 with a New Prototype Inhibitor (ACY-1215) Overcomes Bortezomib Resistance In Multiple Myeloma (MM). <i>Blood</i> , 2010, 116, 2997-2997.	0.6	2
204	Tubacin Kills Epstein-Barr Virus (EBV)-Burkitt Lymphoma Cells by Inducing Reactive Oxygen Species and EBV Lymphoblastoid Cells by Inducing Apoptosis. <i>Journal of Biological Chemistry</i> , 2009, 284, 17102-17109.	1.6	34
205	A pulse at the heart of targeted therapy. <i>Nature Chemical Biology</i> , 2009, 5, 144-145.	3.9	1
206	In Vivo Pharmacodynamic Imaging of Proteasome Inhibition. <i>Molecular Imaging</i> , 2009, 8, 7290.2009.00007.	0.7	40
207	Discovery and Characterization of Macrocyclic Thiopeptide Proteasome Inhibitors for Hematologic Malignancies. <i>Blood</i> , 2008, 112, 3669-3669.	0.6	0
208	A Soft-Drug Histone Deacetylase Inhibitor for Cutaneous T-Cell Lymphoma.. <i>Blood</i> , 2007, 110, 800-800.	0.6	2
209	Targeting Histone Deacetylase 6 and the Aggresome Pathway in Acute Lymphoblastic Leukemia Cells.. <i>Blood</i> , 2007, 110, 1602-1602.	0.6	0
210	Histone Deacetylase-6 (HDAC6) Modulates Akt and STAT3 Activity Via Heat Shock Protein (Hsp) 90 in Human Multiple Myeloma (MM) Cells.. <i>Blood</i> , 2006, 108, 3426-3426.	0.6	0
211	Targeting the Protein Degradation Pathway in Multiple Myeloma with Synergistic, Selective Small Molecules.. <i>Blood</i> , 2005, 106, 2471-2471.	0.6	0